BioNTech (NASDAQ:BNTX) Given New $145.00 Price Target at HC Wainwright

BioNTech (NASDAQ:BNTX) had its price objective lowered by HC Wainwright from $150.00 to $145.00 in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Truist Financial initiated coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Wells Fargo & Company started coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target on the stock. BMO Capital Markets upped their price target on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Morgan Stanley reduced their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Finally, Citigroup assumed coverage on BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Stock Performance

BNTX opened at $90.29 on Tuesday. The business has a 50 day moving average price of $110.45 and a two-hundred day moving average price of $113.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market capitalization of $21.67 billion, a price-to-earnings ratio of -43.00 and a beta of 0.30. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.90 EPS. Research analysts predict that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its stake in shares of BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after acquiring an additional 74,119 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in BioNTech in the third quarter valued at about $2,486,000. Bridgewater Associates LP acquired a new position in BioNTech in the 3rd quarter worth about $674,000. Bamco Inc. NY raised its stake in shares of BioNTech by 88.6% during the 3rd quarter. Bamco Inc. NY now owns 18,574 shares of the company’s stock worth $2,206,000 after purchasing an additional 8,724 shares in the last quarter. Finally, Harbor Advisors LLC acquired a new stake in shares of BioNTech during the 3rd quarter valued at about $238,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.